Figure 1


Tumor Weight (mg)
LXW²/2
Days Post Implantation
Saline Control 200ul,i.p.,qdx10(M-F)
Camptosar 10 mg/kg,i.p.,qdx10(M-F)
huCBE11, 50 µg/inj,i.p.,q7d
huCBE11, 50 µg/inj,i.p.,q7d plus Camptosar, 10 mg/kg,i.p.,qd10 (M-F)
1st Rx
p<0.001 vs huCBE11
0
250
500
750
1000
1250
1500
0
5
10
15
20
25
30
35
40
45

Figure 2


Tumor Weight (mg)
LXW²/2
1000
750
500
250
0
0
5
10
15
20
25
30
Days Post Implantation
1st Rx
p<0.01 vs huCBE11
Saline control 200 ul i.p., q4dx3
Gemcitabine 25 mg/kg i.p., q4dx3
hCBE11 100 µg/inj. i.p. q7d
hCBE11 100 ug/inj i.p.q7d, + Gemcitabine 25 mg/kg i.p., q4dx3

Figure 3


Tumor Weight (mg)
LxW²/2
Days Post Implantation
Saline Control, 0.2 ml/mouse, i.p., Q4Dx3
Taxol, 12.5 mg/kg/inj, i.p., Q4Dx3
huCBE11, 500 µg/100 ul/inj, i.p., Q7D
huCBE11, 500 ug/100 ul/inj, i.p., Q7D plus Taxol, 12.5 mg/kg/inj, i.p., Q4Dx3
1st Rx
p<0.01 vs huCBE11
0
250
500
750
1000
0
5
10
15
20
25
30

Figure 4


Tumor Weight (mg)
LxW²/2
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
45
Days Post Implantation
1st Rx
p<0.001
vs. huCBE11
Saline Control, 0.2 ml/inj, i.p., Q2Dx6 (M,W,F)
CDDP, 2 mg/kg/inj, s.c., Q2Dx6 (M,W,F)
huCBE11, 500 µg/inj, i.p., Q7D
huCBE11, 500 µg/inj, i.p., Q7D
+ CDDP, 2mg/kg/inj, s.c., Q2Dx6 (M,W,F)

Figure 5


Saline Control 200 ul/mouse, i.p., q4Dx3
Adriamycin 6 mg/kg/inj, i.v., q4Dx3
huCBE11 100 µg/100ul//inj., i.p., q7D
huCBE11 100 ug/100ul/inj, i.p., q7D
+ Adriamycin 6 mg/kg/inj, i.v., q4dx3
1st Rx
p=0.001
vs. huCBE11
Tumor Weight (mg)
(LxW²/2)
Days Post Implantation
0
250
500
750
1000
1250
1500
1750
2000
0
5
10
15
20
25
30
35
40

Figure 6


Tumor Weight (mg)
LxW²/2
2000
1500
1000
500
0
0
5
10
15
20
25
30
35
40
45
50
Days Post Implantation
Saline Control, 200 µL
CDDP, 1 mg/kg
hCBE11, 500 µg
hCBE11, 500 µg plus CDDP, 1 mg/kg
CDDP dosing
P<0.05 vs hCBE11

Figure 7


Tumor Weight (mg)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
0
5
10
15
20
25
30
35
40
Days Post Implantation
Saline Control
Adriamycin, 6 mg/kg
hCBE11, 500 µg
hCBE11, 500 ug + Adriamycin, 6 mg/kg
Adriamycin Treatments
Treatments initiated
P<0.001 vs hCBE11 alone

Figure 8


Vehicle Control, 200 µL, IP, QDx10
Camptosar, 3 mg/kg, IP, QDx10
hCBE11, 20 mg/kg, IP, Q7D
hCBE11, 20 mg/kg, IP, Q7D + Camptosar, 3 mg/kg, IP, QDx10
P<0.01 vs hCBE11, 20 mg/kg
Tumor Weight (mg) LxW²/2
Days Post Implantation
0
500
1000
1500
2000
0
10
20
30
40
50
60

Figure 9


Combination Index
2
1.5
1
0.5
0
Synergism
0
0.2
0.4
0.6
0.8
1
Fraction Affected

Figure 10


Day 13
Day 16
Day 20
Day 23
Day 27
Day 30
Day 34
Day 37
Day 41
Combination Index
% Tumor Suppression
0.0
0.2
0.4
0.6
0.8
1.0
0
20
40
60
80
100

Figure 11


Combination Index
2.0
1.5
1.0
0.5
0.0
Synergism
0.0
0.2
0.4
0.6
0.8
1.0
Fraction Affected

Figure 12


Saline Control, 200 µL, IP, Q4Dx3
Gemcitabine, 20 mg/kg, IP, Q4Dx3
hCBE11, 4 mg/kg, IP, Q7D
hCBE11, 4 mg/kg, IP, Q7D
+ Gemcitabine, 20 mg/kg, IP, Q4Dx3
P<0.001
Tumor Weight (mg)
LxW²/2
Days Post Implantation
0
500
1000
1500
2000
2500
3000
0 5 10 15 20 25 30 35 40 45 50 55 60

Figure 13


Day 16
Day 20
Day 23
Day 27
Day 30
Day 34
Day 37
Day 41
Day 43
Combination Index
% Tumor Suppression
0.0
0.2
0.4
0.6
0.8
1.0
0
20
40
60
80
100

Figure 14


Day 16
Day 20
Day 23
Day 27
Day 30
Day 34
Day 37
Day 41
Day 43
% Tumor Suppression
hCBE11 Dose (mg/kg)
Gemcitabine Dose (mg/kg)
0
20
40
60
80
100
0.01
0.1
1
10
100
0.001

Figure 15


Combination Index
2.0
1.5
1.0
0.5
0.0
Synergism
0.0
0.2
0.4
0.6
0.8
1.0
Fraction Affected